Sinco Pharmaceuticals Holdings Limited
Research Sinco Pharmaceuticals Holdings Limited (6833.HK) on Bullrun: market cap HKD 294.77M, P/E 7.3, dividend yield 1.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6833.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryMedical Distribution
- CurrencyHKD
- Market capHKD 294.77M
- P/E7.3
- Dividend yield1.1%
- Financial periodFY2024
- RevenueCNY 2.82B
- Revenue growth11.1%
- Net incomeCNY 42.05M
- Free cash flow-CNY 285.95M
- Gross margin10.6%
Valuation Snapshot
latest market cap is HKD 294.77M; P/E is 7.3; dividend yield is 1.1%.
Peer valuation comparison
Latest P/E is 7.25x versus a Healthcare sector median of 21.69x (66.6% below).
Latest dividend yield is 1.12% versus a Healthcare sector median of 2.41% (53.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | CNY 2.82B | CNY 42.05M | -CNY 285.95M | 10.6% | 0.02 | CNY 308.32M | CNY 350.54M | CNY 662.88M |
| FY2023 | CNY 2.54B | CNY 42.35M | CNY 289.16M | 12.7% | 0.02 | CNY 437.92M | CNY 251.40M | CNY 628.05M |
| FY2022 | CNY 2.27B | CNY 69.46M | CNY 22.39M | 13.5% | 0.03 | CNY 329.14M | CNY 192.41M | CNY 603.81M |
| FY2021 | CNY 2.02B | CNY 135.08M | CNY 282.19M | 18.0% | 0.08 | CNY 326.05M | CNY 340.95M | CNY 374.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 294.77M | 7.3 | 1.2% | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD, yield 1.1%.
| Year | Dividends/share |
|---|---|
| FY2024 | 0 CNY |
| FY2023 | 0.01 CNY |
About Sinco Pharmaceuticals Holdings Limited
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers human albumin serum under the Octapharma, Octapamma, and Octenor name for the treatment of premature infants, hypovolemia, hypoproteinemia, neonatal hyperbilirubinemia, acute respiratory distress syndrome, cardiopulmonary bypass, special types of hemodialysis, and plasma exchange.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sinco Pharmaceuticals Holdings Limited's market cap?
Sinco Pharmaceuticals Holdings Limited's market capitalization is HKD 294.77M.
What is Sinco Pharmaceuticals Holdings Limited's P/E ratio?
Sinco Pharmaceuticals Holdings Limited's price-to-earnings (P/E) ratio is 7.3.
Does Sinco Pharmaceuticals Holdings Limited pay a dividend?
Sinco Pharmaceuticals Holdings Limited has a dividend yield of 1.1%.
What does Sinco Pharmaceuticals Holdings Limited do?
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers human albumin serum under the Octapharma, Octapamma, and Octenor name for the treatment of premature infants, hypovolemia, hypoproteinemia, neonatal hyperbilirubinemia, acute respiratory distress syndrome, cardiopulmonary bypass, special types of hemodialysis, and plasma exchange.